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Abstract
Maladaptive cardiac hypertrophy predisposes one to arrhythmia and sudden death. Cytochrome P450 (CYP)-derived
epoxyeicosatrienoic acids (EETs) promote anti-inflammatory and antiapoptotic mechanisms, and are involved in the
regulation of cardiac Ca2+-, K+- and Na+-channels. To test the hypothesis that enhanced cardiac EET biosynthesis counteracts
hypertrophy-induced electrical remodeling, male transgenic mice with cardiomyocyte-specific overexpression of the human
epoxygenase CYP2J2 (CYP2J2-TG) and wildtype littermates (WT) were subjected to chronic pressure overload (transverse
aortic constriction, TAC) or b-adrenergic stimulation (isoproterenol infusion, ISO). TAC caused progressive mortality that was
higher in WT (42% over 8 weeks after TAC), compared to CYP2J2-TG mice (6%). In vivo electrophysiological studies, 4 weeks
after TAC, revealed high ventricular tachyarrhythmia inducibility in WT (47% of the stimulation protocols), but not in
CYP2J2-TG mice (0%). CYP2J2 overexpression also enhanced ventricular refractoriness and protected against TAC-induced
QRS prolongation and delocalization of left ventricular connexin-43. ISO for 14 days induced high vulnerability for atrial
fibrillation in WT mice (54%) that was reduced in CYP-TG mice (17%). CYP2J2 overexpression also protected against ISO-
induced reduction of atrial refractoriness and development of atrial fibrosis. In contrast to these profound effects on
electrical remodeling, CYP2J2 overexpression only moderately reduced TAC-induced cardiac hypertrophy and did not affect
the hypertrophic response to b-adrenergic stimulation. These results demonstrate that enhanced cardiac EET biosynthesis
protects against electrical remodeling, ventricular tachyarrhythmia, and atrial fibrillation susceptibility during maladaptive
cardiac hypertrophy.
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Introduction
Cytochrome P450 (CYP)-dependent eicosanoids, such as
epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic
acid (20-HETE), may play crucial roles in the development of
heart disease. EETs exert anti-inflammatory and antiapoptotic
effects in cardiomyocytes and ameliorate cardiac ischemia-
reperfusion injury, whereas 20-HETE causes detrimental effects
in the same settings [1–4]. EETs also modulate the electrophys-
iological properties of the heart by regulating L-type Ca2+, Na+,
and ATP-sensitive K+ (KATP) channel activities [5–9]. In isolated
hearts, exogenous EET administration improved postischemic
functional recovery and prevented electrocardiogram abnormal-
ities in the reperfusion phase [10,11]. EET pretreatments also
efficiently reduced myocardial infarction size after transient
coronary artery occlusion [2,12,13]. Further studies revealed an
essential role of EETs in mediating the beneficial effects of pre-
and postconditioning [14–16].
CYP2J2 is the predominant arachidonic acid epoxygenase in
the human heart [17]. CYP2J2-transgenic mice have been
generated as a tool for investigating the impact of increased
endogenous EET biosynthesis on cardiac disease development.
The transgene contains the full-length CYP2J2 cDNA under
control of the aMHC promoter and thus mediates cardiomyocyte-
specific overexpression of the enzyme [18]. CYP2J2 overexpres-
sion reduced infarct size and improved recovery of pump function
as well as ventricular repolarization after ischemia, thereby
mimicking the effects of exogenous EET administration [18,19].
We used CYP2J2-transgenic mice to test the hypothesis that
enhanced cardiac EET biosynthesis prevents arrhythmogenic
substrate formation during the development of maladaptive
cardiac hypertrophy. We induced left ventricular hypertrophy by
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chronic pressure overload to predispose the mice to ventricular
tachyarrhythmia and sudden cardiac death. Alternatively, we
applied long-term isoproterenol infusion to mimic chronic b-
adrenergic stimulation-induced cardiac hypertrophy and thereby
established a model of atrial fibrillation susceptibility. We found
that CYP2J2 overexpression mediated strong antiarrhythmic
effects in both models, suggesting that EETs are involved in
endogenous mechanisms preventing maladaptive electrical re-
modeling during cardiac hypertrophy.
Results
Effect of CYP2J2-overexpression on pressure overload-
induced cardiac hypertrophy
The survival rate during the development of pressure overload-
induced cardiac hypertrophy was significantly higher in CYP2J2-
TG compared to WT mice (Fig. 1A). In WT mice, progressive
mortality started in week 3 after TAC operation. Only 11 out of 19
WT mice (58%) survived over 8 weeks. In contrast, 94% of the
animals (15 out of 16) survived in the CYP2J2-TG group. After
sham surgery, none of the WT (0/17) or CYP2J2-TG mice (0/11)
died over the same post-operational period (Fig. 1A).
TAC induced a strong hypertrophic response (Figs. 1B and 1C)
and severe decline of systolic function (Fig. 1D) in both animal
groups. However, the development of these features was gradually
ameliorated in CYP2J2-TG mice. Eight weeks after TAC, the left
ventricular mass to tibia length-ratio (LVM/TL; Fig. 1B) was
significantly lower (13.160.8 vs. 15.160.8 mg/mm) and the EF
(Fig. 1D) better preserved (20.462.8 vs. 10.761.9%) in CYP2J2-
TG compared to WT mice (compare Table S2 for the full set of
echocardiographic data). CYP2J2-overexpression also moderately
reduced the left ventricular expression of markers of hypertrophy
(ANP and BNP) and fibrosis (Col1 and Col3); however, these
effects as well as changes in the upregulation of bMHC were not
statistically significant (Figs. S1A–E).
Effect of CYP2J2-overexpression on pressure overload-
induced electrical remodeling
Electrophysiological studies were performed 4 weeks after TAC.
This time point was selected to identify features of electrical
remodeling potentially related to the onset of increased mortality
in WT and improved survival of CYP2J2-TG mice (compare
Fig. 1A). TAC-induced cardiac hypertrophy was associated with
significant QRS prolongation in WT but not CYP2J2-TG mice
(Table 1). The ventricular effective refractory period (VERP)
increased in both animal groups after TAC; however, this effect
was significantly more pronounced in CYP2J2-TG compared with
WT mice (Table 1). Four weeks after TAC, the VERP values of
CYP2J2-TG hearts exceeded those of WT hearts by almost 15 ms.
In WT, but not CYP2J2-TG mice, chronic pressure overload
significantly increased the vulnerability to ventricular tachyar-
rhythmia (Fig. 2A). In WT-TAC mice, 47% (7/15) of the
stimulation protocols were effective in contrast to only 14% (3/
21) in the WT-sham group (Fig. 2B). Sustained arrhythmic
episodes lasting longer than 10 consecutive VES predominated in
WT-TAC mice. The sham controls showed mostly either no or
only non-sustained arrhythmias (Fig. 2C). In contrast, CYP2J2-
TG mice were completely resistant. The same PES protocols that
were effective in WT mice did not induce cardiac arrhythmias in
any of the CYP2J2-TG animals 4 weeks after sham or TAC
operation (Fig. 2).
Consistent with the in vivo results, large differences in ventricular
arrhythmia susceptibility were also detectable in Langendorff
preparations of perfused hearts isolated from WT and CYP2J2-
TG mice 4 weeks after TAC (Fig. 2D). Epicardial electrical
stimulation induced ventricular arrhythmias in more than 90% of
the protocols with the hypertrophied WT hearts compared with
only 15% with the corresponding CYP2J2-TG hearts. The high
arrhythmia inducibility of WT-TAC hearts was strongly reduced
after perfusing the organs with the mitochondrial KATP-channel
opener diazoxide for 20 min prior to stimulations (Fig. 2D).
Conversely, the selective EET-antagonist 14,15-EEZE-mSi re-
versed the protection of hypertrophied CYP2J2-TG hearts against
ventricular arrhythmia inducibility (Fig. 2D).
Since gap junctional remodeling may predispose to arrhythmia,
we also analyzed the left ventricles for TAC-induced changes in
the intracellular localization of connexin 43 (Cx43), the major
ventricular gap junction protein (Fig. 3). Double immunostaining
with antibodies directed against Cx43 and N-cadherin revealed a
redistribution of Cx43 from the intercalated discs to the cytoplasm
or lateral boarders in WT mice 4 weeks after TAC. In contrast, the
left ventricles of CYP2J2-TG mice were largely protected against
gap junctional remodeling upon chronic pressure overload.
Typically, the Cx43 expression was preserved in intercalated discs
with only little redistribution (Fig. 3).
Effect of CYP2J2-overexpression on chronic b-adrenergic
stimulation-induced cardiac hypertrophy
Chronic ISO infusion caused moderate cardiac hypertrophy in
both WT and CYP2J2-TG mice (Fig. 4A). After two weeks, the
heart weight to tibia length ratio (HW/TL) was significantly
higher in ISO compared with vehicle treated animals. However,
the hypertrophic response was not different comparing WT and
CYP2J2-TG mice (Fig. 4A). Also, the ISO-induced increases in
heart rate were almost identical in WT and CYP2J2-TG mice
(Table 2). Systolic function (EF) was significantly higher in
CYP2J2-TG compared with WT mice (5962 vs. 4763%) two
weeks after ISO but not vehicle treatment (Fig. 4B; compare Table
S3 for the full set of echocardiographic data).
Effect of CYP2J2-overexpression on chronic b-adrenergic
stimulation-induced electrical remodeling
Chronic b-adrenergic stimulation specifically modulated the
atrial effective refractory period (AERP) without having any
detectable effect on ventricular refractoriness (Table 2). ISO-
treatment strongly decreased the AERP in WT mice. This
shortening of atrial refractoriness was significantly ameliorated in
CYP2J2-TG mice.
In line with its specific effect on atrial refractoriness, ISO
significantly increased the inducibility of atrial but not ventricular
arrhythmia in WT mice (Fig. 5A). After ISO treatment, almost
50% of the PES protocols (13 out of 27 in 9 animals) induced atrial
fibrillation in WT mice compared with only about 9% (2 out of 22
in 8 animals) in the vehicle control (Fig. 5B). We also observed a
higher proportion of atrial fibrillation episodes lasting longer than
30 seconds, which we considered as sustained arrhythmias. The
percentage of animals showing sustained atrial fibrillation in any of
the PES protocols increased from about 30 to 80% comparing
vehicle and ISO-treated WT mice (Fig. 5C).
In contrast to WT mice, CYP2J2-TG mice were largely
protected against the development of atrial fibrillation inducibility.
Two weeks after ISO treatment, CYP2J2-TG mice showed an
atrial fibrillation inducibility of about 17% (4 out of 24 protocols in
8 animals) that was significantly lower than in the corresponding
WT group (Fig. 5B). Also, the relative percentage of induced
sustained fibrillations was markedly lower in CYP2J2-TG than in
WT-mice (Fig. 5C).
CYP2J2 and Arrhythmia
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Chronic b-adrenergic stimulation did not increase the vulner-
ability to ventricular arrhythmia. The ratios of effective vs. total
protocols were 1/24 vs. 3/24 for vehicle and ISO treated WT
mice, and 0/15 vs. 0/24 for vehicle and ISO treated CYP2J2-TG
mice. The ECG parameters of vehicle-treated WT and CYP2J2-
TG mice were not significantly different (Table 2). ISO treatment
for two weeks clearly reduced PQ interval in both animal groups
compared to the vehicle controls. Other ECG parameters
remained essentially unchanged. In particular, ISO treatment
did not induce QRS or QTc prolongation neither in WT nor
CYP2J2-TG mice.
Chronic b-adrenergic stimulation resulted in the development
of atrial fibrosis as indicated by significantly increased Col1, Col3
and fibronectin mRNA levels in ISO- compared to vehicle-treated
WT mice (Figs. 6A–C) and confirmed by Sirius red staining of
atrial sections (Fig. S2). The expression of these features of ISO-
induced atrial fibrosis was clearly ameliorated in CYP2J2-TG mice
(Figs. 6A–C and Fig. S2).
Discussion
Our study shows that cardiomyocyte-specific overexpression of
the human epoxygenase CYP2J2 protects against arrhythmia
susceptibility in two mouse models of cardiac hypertrophy.
CYP2J2-overexpression reduced the vulnerability towards ven-
tricular tachyarrhythmia after chronic pressure overload (TAC
model), and suppressed atrial fibrillation inducibility after chronic
b-adrenergic stimulation (ISO model). The beneficial effects on
cardiac electrical stability occurred without, or only moderately,
reducing the hypertrophic response. Our data suggest that
CYP2J2 overexpression prevented arrhythmogenic substrate
formation primarily by maintaining gap junction integrity in the
TAC model and by attenuating the development of atrial fibrosis
in the ISO model. In isolated hypertrophied hearts, the EET
antagonist 14,15-EEZE-mSi reversed the antiarrhythmic effect of
CYP2J2 overexpression, indicating a direct role of CYP2J2-
derived metabolites in preserving cardiac electrical stability.
Figure 1. Chronic pressure overload-induced mortality and cardiac hypertrophy. (A) The survival rate was significantly higher in CYP2J2-
TG (15 out of 16 animals survived over 8 weeks after TAC operation) compared with WT mice (11/19); Log rank-test `p,0.05. None of the sham
operated WT (n= 17) or CYP2J2-TG mice (n = 11) died over the same period. (B) TAC-induced left ventricular hypertrophy was gradually ameliorated
in CYP2J2-TG compared with WT mice. The difference was significant 8 weeks after TAC (13.160.8 vs. 15.160.8 mg/mm in 15 CYP2J2-TG vs. 11 WT
mice). (C) Myocyte area significantly increased in both WT and CYP2J2-TG mice. (D) Systolic function was significantly decreased in both animal
groups two weeks after TAC compared to the sham controls. Eight weeks after TAC, CYP2J2-TG mice (n = 15) showed significantly higher EF values
(20.462.8 vs. 10.761.9%) than WT littermates (n = 11). Results represent mean6SEM; ANOVA, Post-Hoc Tukey; *p,0.05 vs. WT+Sham; {p,0.05 vs.
CYP+Sham; `p,0.05 vs. WT+TAC.
doi:10.1371/journal.pone.0073490.g001
CYP2J2 and Arrhythmia
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Pressure overload-induced cardiac hypertrophy is associated
with structural and electrical remodeling eventually leading to
heart failure and increased propensity to ventricular tachyarrhyth-
mia and sudden cardiac death [20]. CYP2J2 overexpression
markedly reduced the mortality after TAC. However, cardiac
hypertrophy and decline in pump function were only moderately
ameliorated. Thus, we assumed that the increased survival rate of
CYP2J2-transgenic mice was predominantly related to an
improvement of cardiac electrical stability. Supporting this notion,
ventricular tachyarrhythmia inducibility that strongly increased in
WT mice after TAC was completely suppressed in CYP2J2-TG
mice. Moreover, CYP2J2 TG mice displayed less severe QRS
interval prolongation than WT mice. QRS prolongation indicates
ventricular conduction slowing and has been considered as a
predictor of mortality in congestive heart failure patients [21,22].
In agreement with the antiarrhythmic effect, CYP2J2 overexpres-
sion increased ventricular refractoriness. Prolongation of VERP
protects against reentry tachycardias as known from the mecha-
nism of action of antiarrhythmic drugs. EETs inhibit the open
probability of cardiac Na+-channels resembling the action of Class
I antiarrhythmics such as lidocaine [9]. This effect may have
contributed to the ventricular refractoriness prolongation observed
in CYP2J2-TG mice. Action potential prolongation, as induced by
Class III antiarrhythmics, would provide an alternative explana-
tion. However, in contrast to this expectation, cardiac action
potential duration is significantly shortened in CYP2J2-TG
compared with WT mice [7] and we did not observe QT interval
prolongation.
TAC-induced cardiac hypertrophy was associated with gap
junction remodeling as indicated by delocalization of Cx43 in WT
mice. In contrast, the hypertrophied hearts of CYP2J2-TG mice
showed a preserved Cx43 expression pattern. Reduced and
heterogeneous Cx43 expression causes ventricular conduction
slowing and irregular impulse propagation and thus increases the
risk of fatal ventricular tachyarrhythmia [23,24]. Changes in the
phosphorylation state of Cx43 are obviously responsible for loss of
gap junction integrity during chronic pressure overload.
Providing an impressive proof of this notion, mice expressing
a phosphatase-resistant mutant of Cx43 are protected against
TAC-induced gap junctional remodeling and development of
arrhythmia vulnerability [25]. Our study suggests that CYP2J2-
derived metabolites such as EETs may play a critical role in the
regulation of ventricular Cx43 remodeling. The mechanism
may be related to the capacity of EETs to activate mitochon-
drial KATP channels. Mitochondrial KATP activity is higher in
cardiomyocytes from CYP2J2-TG compared to WT mice and
can be increased in WT cardiomyocytes by exogenous EET
administration [18]. Activation of mitochondrial KATP channels
by ischemic preconditioning or diazoxide protects against
ischemia-induced Cx43 redistribution and electrical uncoupling
[26]. Inhibition of mitochondrial KATP channels blunts
arrhythmia protection in ischemic exercised hearts [27]. In
our study, short-term diazoxide treatment abolished the high
arrhythmia susceptibility of hypertrophied WT hearts, indicat-
ing that increased mitochondrial KATP channel activity would
be indeed sufficient to confer the protection observed in
CYP2J2-TG mice. Indicating a general link between EETs
and connexins, EETs also increase inter-endothelial and
myoendothelial gap junctional communication in the vascula-
ture [28,29]. However, further studies are necessary to
understand the actual molecular mechanisms that may link
EET-mediated mitochondrial K(ATP) channel activation to
protection against Cx43 redistribution and arrhythmia.
Atrial fibrillation is the most common chronic cardiac
arrhythmia in humans [30,31]. Adrenergic stimulation from
catecholamines can cause atrial fibrillation in patients [32]. By
chronic ISO infusion in mice, we have established a new
disease-relevant model for investigating the mechanisms of
arrhythmogenic atrial remodeling. We observed, presumably for
the first time, that chronic b-adrenergic stimulation indeed
enhances atrial fibrillation inducibility without increasing the
vulnerability to ventricular arrhythmia in WT mice. Consistent
with the specificity of this effect, atrial but not ventricular
refractoriness was decreased. CYP2J2-overexpression protected
against AERP shortening and atrial fibrillation induction.
However, CYP2J2 overexpression did not affect the general
hypertrophic or chronotropic response to chronic ISO infusion.
Arrhythmogenic atrial remodeling was associated with increased
fibrosis in WT mice. This feature was significantly ameliorated
in CYP2J2-TG mice. Atrial fibrosis causes conduction abnor-
malities and is generally considered as an important component
of the remodeling process creating the substrate for atrial
fibrillation [33].
Previous studies used inhibitors of the soluble epoxide
hydrolase (sEH) or sEH knockout mice to increase the
cardiovascular EET levels by preventing the metabolism of
EETs to the corresponding less active dihydroxyeicosatrienoic
acids [34]. These measures were highly effective in protecting
against pressure overload- and angiotensin II-induced cardiac
hypertrophy and heart failure. Some of these studies also
showed that blockade of sEH protects against increased cardiac
arrhythmia susceptibility [35,36]. However, whether reduced
arrhythmia vulnerability was a concomitant feature of reduced
hypertrophy and heart failure or due to mechanisms that
specifically ameliorate electrical remodeling remained unclear.
Combined with the results of the present study, we can now
conclude that the epoxy-metabolites produced by CYP2J2 or
stabilized upon sEH inhibition exert a direct antiarrhythmic
effect that protects the heart from arrhythmia even under
conditions of severe hypertrophy and pump failure.
Table 1. Electrophysiological parameters of WT and CYP2J2-
TG mice four weeks after TAC or sham operation.
WT Sham CYP Sham WT TAC CYP TAC
HR (bpm) 459.267.2 483.6617.4 599.3±20.4* 511.8±27.6`
P (ms) 16.760.2 16.560.2 14.4±0.4* 15.860.6
PR (ms) 39.461.1 38.860.7 42.065.5 39.861.0
QRS (ms) 10.960.3 11.760.3 14.0±1.4* 12.060.3
QTc (ms) 53.761.3 58.661.0 55.362.0 54.661.7
AV WB (ms) 73.163.4 73.761.6 69.661.9 69.262.4
AV 2:1 (ms) 52.061.9 52.061.0 53.661.2 50.462.7
AVNERP (ms) 50.261.6 48.061.0 44.361.8 45.660.8
AERP (ms) 20.361.0 14.760.6 16.761.4 18.461.4
VERP (ms) 24.061.4 31.4±0.8* 30.9±2.2* 45.6±1.2*{`
WT – Wildtype; CYP – CYP2J2 overexpressing mice; TAC – Transverse aortic
constriction; HR – Heart rate; bpm – Beats per minute; ms – milliseconds; P – P-
wave duration; PR – PR interval; QRS – QRS interval; QTc – QT interval (corrected
for heart rate); AV WB – 1:1 Atrioventricular node conduction capacity
( =Wenckebach point); AV 2:1 - 2:1 Atrioventricular node conduction capacity;
AVNERP – Atrioventricular node effective refractory period; AERP – Atrial
effective refractory period; VERP - Ventricular effective refractory period.
p,0.05 * vs. WT Sham,
{vs. CYP Sham,
`vs. WT TAC.
doi:10.1371/journal.pone.0073490.t001
CYP2J2 and Arrhythmia
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e73490
Materials and Methods
Detailed Methods are provided in the Online Supplement.
Animals
Male CYP2J2-transgenic mice (CYP-TG) and corresponding
wild-type (WT) littermates [18] were kept on a 12 h/12 h light/
dark cycle in temperature-controlled rooms and fed with standard
chow (ssniff, Soest, Germany) and water ad libitum. All animal
procedures were performed in accordance with the guidelines of
the American Physiological Society and were approved by local
authorities (Landesamt fu¨r Gesundheit und Soziales, Berlin,
Germany).
Pressure overload-induced cardiac hypertrophy
Transverse aortic constriction (TAC) was performed as
described previously [37]. Left ventricular mass (LVM) and
Figure 2. Arrhythmia susceptibility after pressure overload-induced cardiac hypertrophy. (A) Representative original tracings showing
the induction of ventricular tachyarrhythmia by programmed electrical stimulation in WT mice 4 weeks after TAC (upper panel) and the resistance of
TAC operated CYP2J2-TG mice under the same conditions (lower panel). (B) Ventricular arrhythmia inducibility significantly increased in WT mice after
TAC (n = 5) compared with the sham control (n = 7). Arrhythmias were not inducible in any of the CYP2J2-TG mice both after sham (n= 5) and TAC
operation (n = 6). Each animal was subjected to three protocols of programmed electrical stimulation and statistical evaluation was performed as
described in Materials and Methods. (C) The severity of ventricular tachyarrhythmias scored according to the length of induced episodes (number of
consecutive ventricular extrasystoles; VES) increased in WT mice after TAC compared with the sham control, whereas neither non-sustained nor
sustained arrhythmias were inducible in corresponding CYP2J2-TG mice. (D) Analysis of arrhythmia inducibility in Langendorff preparations of
isolated perfused hearts (n = 4 per group). Comparison of the vehicle treated groups confirmed the contrasting vulnerabilities of hypertrophied WT
and CYP2J2-TG hearts after TAC. Perfusion with the mitochondrial KATP-channel opener diazoxide (100 mM, 20 min prior to programmed electrical
stimulation) reduced the arrhythmia inducibility of WT-TAC hearts to the levels of hearts isolated from sham WT mice as well as CYP2J2-TG mice after
TAC. Pretreatment with the EET antagonist 14,15-EEZE-mSi (48.5 mM for 20 min) reversed the protection of hypertrophied CYP2J2-TG hearts towards
arrhythmia inducibility. Results represent mean6SEM; ANOVA, Post-Hoc Tukey; *p,0.05 vs. WT-Sham (vehicle); `p,0.05 vs. WT-TAC (vehicle);
# p,0.05 vs. CYP-TAC (vehicle).
doi:10.1371/journal.pone.0073490.g002
CYP2J2 and Arrhythmia
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Figure 3. Chronic pressure overload-induced alterations in Cx43 localization. (A) Representative immunofluorescence staining of left
ventricular cryosections prepared from WT and CYP2J2-TG mice 4 weeks after TAC surgery. The sections were co-stained for detecting Cx43 (green
fluorescent signal) and N-cadherin (red). Cx43 and N-cadherin are colocalized (yellow) to the intercalated disks (indicated by white arrows). This
normal Cx43 localization was largely preserved in CYP2J2-TG mice, whereas WT mice featured TAC- induced redistribution of Cx43 to the cytoplasm
and lateral borders of the cardiomyocytes (pink arrows). Nuclei were stained with DAPI (blue). Scale bar: 50 mm. (B) Quantitative analysis of Cx43 and
N-cadherin colocalization. Results represent mean6SEM based on the analysis of 5 sections per heart and 4–6 animals per group; ANOVA, Post-Hoc
Tukey; *p,0.05 vs. WT-Sham; `p,0.05 vs. WT-TAC.
doi:10.1371/journal.pone.0073490.g003
Figure 4. Induction of cardiac hypertrophy by chronic b-adrenergic stimulation. (A) Two weeks of chronic ISO infusion significantly
increased the heart weight to tibia length-ratio in WT and CYP2J2-TG mice (n = 7 per group) compared with the vehicle controls (n = 7 and 5). The
hypertrophic response was not different in CYP2J2-TG compared to WT mice. (B) Systolic function was not significantly altered upon chronic ISO
infusion as indicated by preserved EF values compared to the respective vehicle controls. EF was slightly but significantly higher in CYP2J2-TG than
WT mice two weeks after chronic ISO stimulation. Results represent mean6SEM; ANOVA, Post-Hoc Tukey; *p,0.05 vs. WT+Vehicle; {p,0.05 vs.
CYP+Vehicle; `p,0.05 vs. WT+ISO.
doi:10.1371/journal.pone.0073490.g004
CYP2J2 and Arrhythmia
PLOS ONE | www.plosone.org 6 August 2013 | Volume 8 | Issue 8 | e73490
Table 2. Electrophysiological parameters of WT and CYP2J2-TG mice two weeks after chronic vehicle or isoproterenol infusion.
WT Vehicle CYP Vehicle WT ISO CYP ISO
HR (bpm) 509.0614.7 507.8639.5 650.7±3.9* 642.9±7.4{
P (ms) 16.160.4 15.460.2 15.860.4 16.860.2
PQ (ms) 38.860.9 39.261.0 35.3±0.6* 34.5±0.8{
QRS (ms) 10.560.3 10.860.4 9.660.2 10.560.2
QTc (ms) 53.161.1 52.660.8 49.760.9 51.461.0
AV WB (ms) 71.361.3 67.560.5 67.861.0 70.061.8
AV 2:1 (ms) 52.060.5 5061.6 49.660.6 53.361.4
AVNERP (ms) 48.761.3 46.361.1 46.761.2 48.7±1.3`
AERP (ms) 21.760.9 22.261.1 13.1±0.5* 18.0±0.7{`
VERP (ms) 28.961.0 36.161.9 30.560.6 36.860.6
WT – Wildtype; CYP – CYP2J2 overexpressing mice; TAC – Transverse aortic constriction; HR – Heart rate; bpm – Beats per minute; ms – milliseconds; P – P-wave
duration; PR – PR interval; QRS – QRS interval; QTc – QT interval (corrected for heart rate); AV WB – 1:1 Atrioventricular node conduction capacity ( =Wenckebach point);
AV 2:1 - 2:1 Atrioventricular node conduction capacity; AVNERP – Atrioventricular node effective refractory period; AERP – Atrial effective refractory period; VERP -
Ventricular effective refractory period.
p,0.05 * vs. WT Vehicle.
{vs. CYP Vehicle.
`vs. WT ISO.
doi:10.1371/journal.pone.0073490.t002
Figure 5. Arrhythmia susceptibility after chronic b-adrenergic stimulation-induced cardiac hypertrophy. (A) Representative original
tracings showing the induction of atrial fibrillation by programmed electrical stimulation in WT mice 2 weeks after chronic ISO infusion (upper panel)
and the resistance of CYP2J2-TG mice treated in the same manner (lower panel). (B) Atrial fibrillation inducibility significantly increased in WT mice
after chronic ISO infusion (n = 9) compared with the vehicle control (n = 8) and was significantly higher than in CYP2J2-TG mice (n = 7 and n= 8 for the
vehicle and ISO groups). (C) The relative percentage of inducible sustained atrial fibrillation was markedly higher in WT compared with CYP2J2-TG
after chronic ISO infusion. For statistical evaluation of arrhythmia inducibilities and severity scoring compare Fig. 2. Results represent mean6SEM;
ANOVA, Post-Hoc Tukey; *p,0.05 vs. WT+Vehicle; {p,0.05 vs. CYP+Vehicle; `p,0.05 vs. WT+ISO.
doi:10.1371/journal.pone.0073490.g005
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ejection fraction (EF) were determined by echocardiography
following published procedures [38]. Cohort 1 was analyzed four
weeks after TAC by ECG and electrophysiological studies in vivo or
in an isolated heart system. Cohort 2 was sacrificed eight weeks
after TAC or sham surgery.
Cardiac hypertrophy upon chronic b-adrenergic
stimulation
ISO was continuously infused via subcutaneously implanted
osmotic minipumps (Alzet) at a rate of 40 mg/kg/d for two weeks.
Echocardiography was performed before and after 13 days of ISO
infusion. After two weeks of treatment, ECG and electrophysio-
logical data were recorded.
In vivo electrophysiological studies
Programmed electrical stimulation (PES) was performed in the
right atrium or right ventricle using a digital electrophysiology lab
(EP Tracer; CardioTek) to determine refractory periods and
arrhythmia inducibility [39]. Atrial arrhythmias were defined as
fast (.800 bpm) electrical activity in the right atrial electrograms,
with ECG P waves different to normal sinus rhythm and
subsequent fast, but physiological activation of the ventricles
(ECG R wave and right ventricular electrograms similar to normal
sinus rhythm). Atrial fibrillation was defined as fast, irregular
activity in the right atrial electrograms with irregular conduction
to the ventricles (high variability of R-R intervals). Ventricular
arrhythmias were defined by fast (.800 bpm) activity originating
from the ventricular myocardium (change in morphology of ECG
R waves and local right ventricular electrograms compared to
normal sinus rhythm). During inhalation anesthesia with isoflur-
ane (2% with 360 ml/min air flow; Univentor 400 anesthesia
unit), the animals’ body temperature was kept constant at 37uC
using a homeothermic blanket control unit (Hugo Sachs
Elektronik, Harvard Apparatus) with rectal temperature control.
After preparation of the right jugular vein, a 2 French octapolar
electrophysiology catheter (CIB’ER mouse cath; NuMed) was
placed in the right heart, including atrium and ventricle. PES was
performed using a standardized protocol that included trains of 10
basal stimuli (S1) followed by up to 3 extra stimuli (S2–S4),
delivered with a coupling interval decreasing in steps of 5 ms until
ventricular or atrial refractoriness was reached. The stimulation
procedures were repeated at three different basal cycle lengths
(100 ms, 90 ms, 80 ms) with each animal. Occurrence and
duration of inducible arrhythmias were documented. Only
stimulation protocols with reproducible arrhythmias longer than
five consecutive beats in ventricle and episodes longer than 350 ms
in the atria were considered positive. ‘‘Arrhythmia inducibility’’
Figure 6. Effect of chronic b-adrenergic stimulation on the expression of markers of fibrosis in WT and CYP2J2-TG mice. RNA isolated
from atrial tissue 2 weeks after vehicle or ISO infusion was reverse transcribed and analyzed by quantitative Taqman- or SYBR-PCR for the expression
of Col1 (A), Col3 (B) and fibronectin (C). WT+Vehicle: n = 8; CYP+Vehicle n = 5; WT+ISO: n = 10; CYP+ISO: n = 8. ANOVA, Post-Hoc Tukey; *p,0.05 vs.
WT+vehicle {p,0.05 vs. CYP+vehicle; `p,0.05 vs. WT+ISO.
doi:10.1371/journal.pone.0073490.g006
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was calculated as the percentage of effective (positive) out of total
protocols applied. Accordingly, the arrhythmia inducibility of
individual animals could take a value of 0, 33, 66 or 100%. For
statistical evaluation, the data obtained for the individual animals
in a given group were averaged and are given as mean6SEM. For
scoring the severity of induced arrhythmias, three response
categories were defined: sustained ($10 consecutive ventricular
extrasystoles, VES or atrial fibrillation episodes $30 sec in at least
one protocol), non-sustained (,10 VES or atrial fibrillation
episodes ,30 sec in at least one protocol) and no arrhythmias in
all three protocols. The data are given as percentage of animals in
a given group assigned to these categories.
Electrocardiography (ECG)
Standard limb lead surface ECGs were recorded under slight
isoflurane anesthesia using skin electrodes. Calculation of standard
ECG time-interval parameters were performed by two indepen-
dent operators based on averaged ECG lead II waveforms.
Corrections for heart rate and definition of time points were made
as described previously [39].
Langendorff preparation of isolated hearts
The mice were injected i.p. with 40 I.U. of Heparin-Na in
PBS and were sacrificed after 10 min. Hearts were rapidly
excised and placed in ice-cold modified Krebs-Henseleit buffer,
and the aortas were cannulated. The mounted hearts were
perfused in a retrograde fashion at constant pressure (60 mm
Hg) with continuously aerated (95% O2–5% CO2) modified
Krebs-Henseleit buffer containing (in mmol/l) 118 NaCl, 4.7
KCl, 1.2 MgSO4, 1.5 CaCl2, 24.7 NaHCO3, 0.23 KH2PO4,
0.06 EDTA and 11.1 glucose, at a temperature of 37uC. The
hearts were stabilized for 10 min and then treated for 20 min
with either the mitochondrial KATP-channel opener diazoxide
(100 mmol/l in the perfusion buffer), a selective EET-antagonist
(48.5 mmol/l 14,15-epoxyeicosa-5(Z)-enoic-methylsulfonyli-
mide; 14,15-EEZE-mSI [40]) or as control with vehicle (0.1%
dimethylsulfoxide; DMSO). A pacing electrode was placed at
the left ventricle and the same PES protocols to determine
ventricular refractoriness and inducibility of ventricular ar-
rhythmias were performed as used in vivo.
Histology
In the TAC model, frozen tissue was embedded in O.C.T-
Tissue Tek (Sakura, Netherland) and cut in 2 mm sections.
Connexin 43 (Cx43) was stained using anti-Cx43 antibody
(1:1000; from Sigma-Aldrich) and Alexa488-conjugated secondary
anti-rabbit antibody (1:500; Jackson-Immuno Research). Gap
junction protein N-cadherin was stained using anti-N-cadherin
antibody (3 mg/ml; from Invitrogen) and secondary Cy3-conju-
gated secondary anti-mouse antibody (1:300; Dianova). Cx43
location was quantified by determining the colocalization of Cx43
and N-cadherin in the intercalated discs as described before [25].
Myocyte area was measured from cross-sectional area of
cardiomyocytes stained by wheat germ agglutinin (WGA) labeled
with Oregon Green 488 (1:500; Life Technologies).
Gene expression
mRNA levels of atrial and brain natriuretic peptides (ANP and
BNP) bmyosin heavy chain (bMHC), collagen 1 and 3 (Col1 and
Col3), and fibronectin were determined by Taqman or SYBR RT-
PCR protocols using 18S RNA as endogenous control. The
primers used are given in Table S1.
Data analysis and statistics
All data were tested for normal distribution and are given as
mean6SEM. Data were analyzed by a two-way ANOVA and post
hoc Tukey’s test using SPSS17 for Windows. Survival differences
were analyzed by the log-rank test. P-values,0.05 were defined as
statistically significant.
Supporting Information
Materials S1 Supplementary material.
(DOC)
Figure S1 Effect of chronic pressure overload on the
expression of markers of hypertrophy and fibrosis in
WT and CYP2J2-TG mice.
(DOCX)
Figure S2 Effect of chronic b-adrenergic stimulation on
atrial fibrosis in WT and CYP2J2-TG mice.
(DOCX)
Table S1 Primer sequences for quantitative real-timeRT-PCR.
(DOCX)
Table S2 Summary of echocardiographic data eight weeks after
TAC.
(DOCX)
Table S3 Summary of echocardiographic data after two weeks
of b-adrenergic stimulation.
(DOCX)
Acknowledgments
Christina Westphal and Bastian Spallek as well as Robert Fischer and
Wolf-Hagen Schunck contributed equally. We thank Christel Andre`e,
Astrid Schiche, Jutta Meisel, Ilona Kamer, May-Britt Ko¨hler and Gabriele
Ndiaye for excellent technical assistance.
Author Contributions
Conceived and designed the experiments: CW BS CS VRZ DNM WHS
RF. Performed the experiments: CW BS AK LM FQ. Analyzed the data:
CW BS AK LM. Contributed reagents/materials/analysis tools: LMD CS
JAB VRZ JRF DCZ DNM WHS RF. Wrote the paper: CW WHS RF.
References
1. Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, et al. (2005) Cytochrome P450
and arachidonic acid metabolites: role in myocardial ischemia/reperfusion
injury revisited. Cardiovasc Res 68: 18–25.
2. Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ (2007) Role of
epoxyeicosatrienoic acids in protecting the myocardium following ischemia/
reperfusion injury. Prostaglandins Other Lipid Mediat 82: 50–59.
3. Nithipatikom K, Gross GJ (2010) Review article: epoxyeicosatrienoic acids:
novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther 15: 112–
119.
4. Nithipatikom K, Gross ER, Endsley MP, Moore JM, Isbell MA, et al. (2004)
Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous
cardioprotective pathway. Circ Res 95: e65–71.
5. Xiao YF, Huang L, Morgan JP (1998) Cytochrome P450: a novel system
modulating Ca2+ channels and contraction in mammalian heart cells. J Physiol
508 (Pt 3): 777–792.
6. Xiao YF, Ke Q, Seubert JM, Bradbury JA, Graves J, et al. (2004) Enhancement
of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific
overexpression of CYP2J2. Mol Pharmacol 66: 1607–1616.
7. Ke Q, Xiao YF, Bradbury JA, Graves JP, Degraff LM, et al. (2007)
Electrophysiological properties of cardiomyocytes isolated from CYP2J2
transgenic mice. Mol Pharmacol 72: 1063–1073.
8. Lu T, Hoshi T, Weintraub NL, Spector AA, Lee HC (2001) Activation of ATP-
sensitive K(+) channels by epoxyeicosatrienoic acids in rat cardiac ventricular
myocytes. J Physiol 537: 811–827.
CYP2J2 and Arrhythmia
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e73490
9. Lee HC, Lu T, Weintraub NL, VanRollins M, Spector AA, et al. (1999) Effects
of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat
ventricular myocytes. J Physiol 519 Pt 1: 153–168.
10. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, et al. (1997) Molecular
cloning, expression, and functional significance of a cytochrome P450 highly
expressed in rat heart myocytes. J Biol Chem 272: 12551–12559.
11. Batchu SN, Law E, Brocks DR, Falck JR, Seubert JM (2009) Epoxyeicosa-
trienoic acid prevents postischemic electrocardiogram abnormalities in an
isolated heart model. J Mol Cell Cardiol 46: 67–74.
12. Gross GJ, Hsu A, Falck JR, Nithipatikom K (2007) Mechanisms by which
epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell
Cardiol 42: 687–691.
13. Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, et al. (2008) Effects
of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by
exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ
Physiol 294: H2838–2844.
14. Gross GJ, Gauthier KM, Moore J, Campbell WB, Falck JR, et al. (2009)
Evidence for role of epoxyeicosatrienoic acids in mediating ischemic precondi-
tioning and postconditioning in dog. Am J Physiol Heart Circ Physiol 297: H47–
52.
15. Yu GG, Zeng XJ, Wang HX, Lu LQ, Zheng SP, et al. (2011) Cytochrome P450
2J3/epoxyeicosatrienoic acids mediate the cardioprotection induced by
ischaemic post-conditioning, but not preconditioning, in the rat. Clin Exp
Pharmacol Physiol 38: 63–70.
16. Gross GJ, Baker JE, Moore J, Falck JR, Nithipatikom K (2011) Abdominal
Surgical Incision Induces Remote Preconditioning of Trauma (RPCT) via
Activation of Bradykinin Receptors (BK2R) and the Cytochrome P450
Epoxygenase Pathway in Canine Hearts. Cardiovasc Drugs Ther.
17. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC (1996) Molecular cloning
and expression of CYP2J2, a human cytochrome P450 arachidonic acid
epoxygenase highly expressed in heart. J Biol Chem 271: 3460–3468.
18. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, et al. (2004) Enhanced
postischemic functional recovery in CYP2J2 transgenic hearts involves
mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ
Res 95: 506–514.
19. Edin ML, Wang Z, Bradbury JA, Graves JP, Lih FB, et al. (2011) Endothelial
expression of human cytochrome P450 epoxygenase CYP2C8 increases
susceptibility to ischemia-reperfusion injury in isolated mouse heart. Faseb J
25: 3436–3447.
20. Wang Y, Hill JA (2010) Electrophysiological remodeling in heart failure. J Mol
Cell Cardiol 48: 619–632.
21. Boulaksil M, Noorman M, Engelen MA, van Veen TA, Vos MA, et al. (2010)
Longitudinal arrhythmogenic remodelling in a mouse model of longstanding
pressure overload. Neth Heart J 18: 509–515.
22. Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN (2002) QRS duration
and mortality in patients with congestive heart failure. Am Heart J 143: 1085–
1091.
23. Severs NJ, Bruce AF, Dupont E, Rothery S (2008) Remodelling of gap junctions
and connexin expression in diseased myocardium. Cardiovasc Res 80: 9–19.
24. Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, et al. (2001)
Conduction slowing and sudden arrhythmic death in mice with cardiac-
restricted inactivation of connexin43. Circ Res 88: 333–339.
25. Remo BF, Qu J, Volpicelli FM, Giovannone S, Shin D, et al. (2011)
Phosphatase-resistant gap junctions inhibit pathological remodeling and prevent
arrhythmias. Circ Res 108: 1459–1466.
26. Jain SK, Schuessler RB, Saffitz JE (2003) Mechanisms of delayed electrical
uncoupling induced by ischemic preconditioning. Circ Res 92: 1138–1144.
27. Quindry JC, Schreiber L, Hosick P, Wrieden J, Irwin JM, et al. (2010)
Mitochondrial KATP channel inhibition blunts arrhythmia protection in
ischemic exercised hearts. Am J Physiol Heart Circ Physiol 299: H175–183.
28. Popp R, Brandes RP, Ott G, Busse R, Fleming I (2002) Dynamic modulation of
interendothelial gap junctional communication by 11,12-epoxyeicosatrienoic
acid. Circ Res 90: 800–806.
29. Bolognesi M, Zampieri F, Di Pascoli M, Verardo A, Turato C, et al. (2011)
Increased myoendothelial gap junctions mediate the enhanced response to
epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of
cirrhotic rats. Liver Int 31: 881–890.
30. Falk RH (2001) Atrial fibrillation. N Engl J Med 344: 1067–1078.
31. Iwasaki YK, Nishida K, Kato T, Nattel S (2011) Atrial fibrillation
pathophysiology: implications for management. Circulation 124: 2264–2274.
32. Workman AJ (2010) Cardiac adrenergic control and atrial fibrillation. Naunyn
Schmiedebergs Arch Pharmacol 381: 235–249.
33. Burstein B, Nattel S (2008) Atrial fibrosis: mechanisms and clinical relevance in
atrial fibrillation. J Am Coll Cardiol 51: 802–809.
34. Qiu H, Li N, Liu JY, Harris TR, Hammock BD, et al. (2010) Soluble Epoxide
Hydrolase Inhibitors and Heart Failure. Cardiovasc Ther 29: 99–111.
35. Xu D, Li N, He Y, Timofeyev V, Lu L, et al. (2006) Prevention and reversal of
cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad
Sci U S A 103: 18733–18738.
36. Monti J, Fischer J, Paskas S, Heinig M, Schulz H, et al. (2008) Soluble epoxide
hydrolase is a susceptibility factor for heart failure in a rat model of human
disease. Nat Genet 40: 529–537.
37. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, et al. (2010) Female
sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in
pressure overload. Am J Physiol Regul Integr Comp Physiol 298: R1597–1606.
38. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA (2002)
Recommendations for quantification of Doppler echocardiography: a report
from the Doppler Quantification Task Force of the Nomenclature and
Standards Committee of the American Society of Echocardiography. J Am
Soc Echocardiogr 15: 167–184.
39. Fischer R, Dechend R, Qadri F, Markovic M, Feldt S, et al. (2008) Dietary n-3
polyunsaturated fatty acids and direct renin inhibition improve electrical
remodeling in a model of high human renin hypertension. Hypertension 51:
540–546.
40. Gauthier KM, Jagadeesh SG, Falck JR, Campbell WB (2003) 14,15-
epoxyeicosa-5(Z)-enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine
coronary arteries. Hypertension 42: 555–561.
CYP2J2 and Arrhythmia
PLOS ONE | www.plosone.org 10 August 2013 | Volume 8 | Issue 8 | e73490
